W

Wugen

94 employees

Wugen is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Therapeutics

Date founded

2018

Funding rounds raised

Total raised

$172M

from 5 investors over 5 rounds

W

Wugen raised $172M on July 15, 2021

Investors: RiverVest Venture Partners, Aisling Capital, Sands Capital Management, Intermediate Capital Group (ICG) and LYZZ CAPITAL

FAQ